• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Dips 200 Points; TJX Posts Upbeat Sales

    2/28/24 10:12:21 AM ET
    $ADIL
    $BETS
    $IAS
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Restaurants
    Consumer Discretionary
    Get the next $ADIL alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday.

    Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ fell 0.63% to 15,933.71. The S&P 500 also fell, dropping, 0.33% to 5,061.21.

    Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Energy shares rose by 0.5% on Wednesday.

    In trading on Wednesday, information technology shares fell by 0.8%.

     

    Top Headline

     

    The TJX Companies, Inc. (NYSE:TJX) posted better-than-expected sales for its fourth quarter on Wednesday.

    TJX Companies posted GAAP earnings of $1.12 per share, in-line with market estimates. The company’s quarterly sales came in at $16.40 billion, versus expectations of $16.21 billion.

    TJX said it sees FY25 earnings of $3.94 to $4.02 per share, versus estimates of $4.11 per share. The company expects consolidated comparable store sales gaining 2% to 3%.

     

    Equities Trading UP

     

    Vivani Medical, Inc. (NASDAQ:VANI) shares shot up 390% to $4.9478 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.

    Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) got a boost, surging 124% to $1.8969. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.

    Bit Brother Limited (NASDAQ:BETS) shares were also up, gaining 63% to $4.0617.

     

    Equities Trading DOWN

     

    Oragenics, Inc. (NYSE:OGEN) shares dropped 45% to $1.35. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.

    Shares of Integral Ad Science Holding Corp. (NASDAQ:IAS) were down 39% to $10.39 after the company reported fourth-quarter financial results.

    Palatin Technologies, Inc. (NYSE:PTN) was down, falling 36% to $2.55 after the company reported results of PL9643 MELODY-1 pivotal Phase 3 clinical trial in patients with dry eye disease.

    Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

     

    Commodities

     

    In commodity news, oil traded up 0.8% to $79.53 while gold traded down 0.2% at $2,040.70.

    Silver traded fell 0.8% to $22.575 on Wednesday while copper fell 0.7% to $3.8255.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.4%, London’s FTSE 100 fell 0.7% while Spain’s IBEX 35 Index fell 0.3% The German DAX gained 0.1% French CAC 40 fell 0.1% while Italy’s FTSE MIB Index declined 0.3%.

    The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Wednesday, with Japan’s Nikkei 225 falling 0.08%, Hong Kong’s Hang Seng Index dipping 1.51%, China’s Shanghai Composite Index tumbling 1.91% and India’s S&P BSE Sensex falling 1.08%.

    Hong Kong’s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.

     

    Economics

     

    U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.

    The US economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.

    The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.

    U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.

    Now Read This: Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $BETS
    $IAS
    $OGEN

    CompanyDatePrice TargetRatingAnalyst
    TJX Companies Inc.
    $TJX
    1/8/2026Buy
    Deutsche Bank
    Palatin Technologies Inc.
    $PTN
    12/12/2025$60.00Buy
    Laidlaw
    TJX Companies Inc.
    $TJX
    12/10/2025$175.00Buy
    Guggenheim
    Palatin Technologies Inc.
    $PTN
    12/3/2025$50.00Buy
    Alliance Global Partners
    TJX Companies Inc.
    $TJX
    11/20/2025$155.00 → $170.00Outperform
    Telsey Advisory Group
    TJX Companies Inc.
    $TJX
    10/15/2025$165.00Buy
    BTIG Research
    TJX Companies Inc.
    $TJX
    9/5/2025Buy
    Erste Group
    TJX Companies Inc.
    $TJX
    8/21/2025$150.00 → $155.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $ADIL
    $BETS
    $IAS
    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

    GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation incorporates Senate Report 119-55, which includes a significant Congressional directive to the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA) to collaborate on

    2/4/26 9:35:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

    GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the "Reverse Split") of its common stock, par value $0.001 per share ("Common Stock"), that will become effective on February 5, 2026 at 11:59 p.m. Eastern Time (the "Effective Time"). Adial's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "ADIL" and will begin trading on a split-adjusted basis when the Nasdaq opens o

    2/3/26 4:05:00 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

    Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida. "Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal t

    2/2/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    SEC Filings

    View All

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    2/4/26 4:30:34 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 4:11:14 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Vivani Medical Inc.

    424B5 - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 6:01:48 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lane Amy B gifted 174 shares and bought $7,915 worth of shares (116 units at $68.23), decreasing direct ownership by 3% to 29,007 units (SEC Form 4)

    4 - TJX COMPANIES INC /DE/ (0000109198) (Issuer)

    2/3/26 7:00:03 PM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lane Amy B gifted 174 shares and bought $7,915 worth of shares (116 units at $68.23), decreasing direct ownership by 3% to 29,007 units (SEC Form 4)

    4 - TJX COMPANIES INC /DE/ (0000109198) (Issuer)

    2/3/26 7:00:03 PM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Director Telling Fred sold $198 worth of shares (210 units at $0.94), decreasing direct ownership by 18% to 948 units (SEC Form 4)

    4/A - ORAGENICS INC (0001174940) (Issuer)

    1/22/26 1:04:30 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on TJX

    Deutsche Bank initiated coverage of TJX with a rating of Buy

    1/8/26 10:58:50 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Laidlaw initiated coverage on Palatin Technologies with a new price target

    Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00

    12/12/25 8:54:18 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on TJX with a new price target

    Guggenheim initiated coverage of TJX with a rating of Buy and set a new price target of $175.00

    12/10/25 8:40:06 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ADIL
    $BETS
    $IAS
    $OGEN
    Leadership Updates

    Live Leadership Updates

    View All

    IAS APPOINTS MELISSA FURZE AS HEAD OF DATA SCIENCE

    Former LinkedIn executive to scale IAS's data science and AI capabilities worldwide NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Integral Ad Science (NASDAQ:IAS), a leading global media measurement and optimization platform, today announced that Melissa Furze joined the company as Head of Data Science at IAS reporting to the Chief Technology Officer. Melissa will lead the company's global data science, AI, and analytics strategy, partnering closely with product, engineering, and the commercial teams to accelerate innovation, strengthen protection and performance capabilities, and deliver trusted, data-driven outcomes for advertisers and publishers worldwide.

    12/22/25 8:00:00 AM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    TJ Maxx Hits the Road with the First-Ever "Maxxinista Express" Holiday Tour Inspired by its Iconic Superfans

    A one-of-a-kind double-decker tour bus experience will travel across the country with festive stops in three cities to amp up the fun of holiday shopping at multiple TJ Maxx stores in search of the best finds and gifts FRAMINGHAM, Mass., Dec. 4, 2025 /PRNewswire/ -- This holiday season, TJ Maxx (NYSE:TJX) is gifting Maxxinistas a magical experience with the debut of the Maxxinista Express, a first-of-its-kind double-decker bus taking superfans on a TJ Maxx road trip in select cities throughout December. The festive tour will bring select fans into a Maxxinista wonderland amidst a full day of shopping with stops at three beloved TJ Maxx stores in their cities so they can hunt for thoughtful g

    12/4/25 11:16:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

    Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

    8/13/25 4:20:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integral Ad Science Holding Corp.

    SC 13G/A - INTEGRAL AD SCIENCE HOLDING CORP. (0001842718) (Subject)

    11/14/24 6:19:26 PM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Financials

    Live finance-specific insights

    View All

    The TJX Companies, Inc. Announces Quarterly Common Stock Dividend

    The TJX Companies, Inc. (NYSE:TJX) today announced the declaration of a quarterly dividend on its common stock of $.425 per share payable March 5, 2026, to shareholders of record on February 12, 2026. About The TJX Companies, Inc. The TJX Companies, Inc., a Fortune 100 company, is the leading off-price retailer of apparel and home fashions in the U.S. and worldwide. Our mission is to deliver great value to customers every day. We do this by offering a rapidly changing assortment of quality, fashionable, brand name, and designer merchandise at prices generally 20% to 60% below full-price retailers' regular prices on comparable merchandise. We operate over 5,100 stores across nine countries

    12/9/25 3:35:00 PM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    The TJX Companies, Inc. Reports Q3 FY26 Results; Comp Sales Growth of 5%, Pretax Profit Margin of 12.7%, and Diluted EPS of $1.28 All Well Above Plan; Increases FY26 Comp Sales Growth, Pretax Profit Margin, and EPS Guidance

    Q3 consolidated comparable sales increased 5%, well above the Company's plan Q3 pretax profit margin of 12.7%, well above the Company's plan Q3 diluted earnings per share of $1.28, up 12% and well above the Company's plan Returned $1.1 billion to shareholders in Q3 through share repurchases and dividends Increases full year FY26 comp sales growth, pretax profit margin, and diluted earnings per share guidance The TJX Companies, Inc. (NYSE:TJX), the leading off-price apparel and home fashions retailer in the U.S. and worldwide, today announced sales and operating results for the third quarter ended November 1, 2025. Net sales for the third quarter of Fiscal 2026 were $15.1 bil

    11/19/25 7:30:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    The TJX Companies, Inc. to Report Q3 FY26 Results November 19, 2025

    The TJX Companies, Inc. (NYSE:TJX) today announced that it plans to release its third quarter Fiscal 2026 sales and earnings results on Wednesday, November 19, 2025, before 9:30 a.m. ET. At 11:00 a.m. ET that day, Ernie Herrman, TJX's Chief Executive Officer and President, will hold a conference call to discuss the Company's third quarter Fiscal 2026 results, operations, and business trends. A real-time webcast of the call will be available to the public at TJX.com. A replay of the call will also be available by dialing (866) 367-5577 (toll free) or (203) 369-0233 through Tuesday, November 25, 2025, or at TJX.com. About The TJX Companies, Inc. The TJX Companies, Inc., a Fortune 100 compa

    11/5/25 11:16:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary